Neuromedika - Company finances
|
EUR
|
2023
From: 2023-03-07
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 2,311 | 3,815 | 3,305 |
| Profit before tax | - | - | - |
| Net profit | -3,133 | -2,296 | -4,374 |
| Equity | -633 | -2,929 | -7,303 |
| Liabilities | 7,711 | 8,909 | 7,303 |
| Non-current assets | 6,800 | 5,200 | 0 |
| Current assets | 278 | 780 | 0 |
| Total assets | 7,078 | 5,980 | 0 |
|
Taxes paid
|
|||
| STI taxes | 81 | 108 | 136 |
|
Financial indicators
|
|||
| Revenue change y/y | - | +65.1% | -13.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -44.3% | -38.4% | - |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -135.6% | -60.2% | -132.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 2,311 | 3,052 | 1,803 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Neuromedika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-01-16 | 2026-01-31 | 0.06 |
| 2025-12-16 | 2025-12-16 | 0.06 |
| 2025-11-18 | 2025-12-09 | 0.06 |
| 2025-10-23 | 2025-11-11 | 0.06 |
| 2025-08-28 | 2025-08-29 | 55.03 |
| 2025-08-19 | 2025-08-21 | 55.03 |
| 2025-02-18 | 2025-02-20 | 3.45 |
| 2024-01-16 | 2024-01-18 | 0.04 |
| 2023-12-18 | 2024-01-11 | 0.04 |
| 2023-11-16 | 2023-12-13 | 0.04 |
| 2023-10-30 | 2023-11-08 | 0.04 |
| 2023-10-25 | 2023-10-25 | 0.04 |
| 2023-09-18 | 2023-09-20 | 9.19 |
| 2023-08-17 | 2023-08-21 | 9.20 |
| 2023-07-24 | 2023-08-16 | 0.01 |
| 2023-05-16 | 2023-05-17 | 9.19 |
Neuromedika - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Neuromedika is: 1 €
| From | To | Overdue, € |
|---|---|---|
| 2026-02-14 | 2026-09-02 | 1.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Neuromedika, UAB (code 306267461) is a Private Limited Liability Company operating in other human health activities n.e.c. In the latest financial year, 2025, the company generated revenue of €3.3K and recorded a net loss of €4.4K, resulting in a negative profit margin of -132.3%. Revenue declined by 13.4% year on year from €3.8K in 2024, although it remained 43.0% above the €2.3K reported in 2023. Profitability improved in 2024 compared with 2023, when the company posted a €3.1K loss, but the loss widened again in 2025. The balance sheet remains weak: equity stood at -€7.3K and liabilities at €7.3K in 2025. In the previous year, total assets were €6.0K, with long-term assets of €5.2K and short-term assets of €780, indicating a very small asset base. Staff productivity was modest, with revenue per employee of €3.3K and a loss per employee of €4.4K in 2025. Return and leverage ratios should be interpreted cautiously given the negative equity position.